Congress moves to map hidden vulnerabilities in America's drug supply
H.R. 4191 — MAPS Act · Filed by Doris Matsui (D-CA) · 2 cosponsors · Introduced Jun 26, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Health and Human Services to create and maintain a list of essential medicines critical to national security and public health, assess the vulnerabilities in their supply chains, and map those supply chains using data analytics to identify risks. The bill requires federal agencies to coordinate, share information about drug manufacturing locations and production volumes, and report annually to Congress on supply chain vulnerabilities and shortages.
Why we flagged it
The bill's core mechanism is creating federal visibility into drug supply chains through mapping, risk assessment, and inter-agency coordination. It is fundamentally a transparency and coordination measure aimed at identifying and mitigating national security and public health risks.
What the text implies
- The bill grants HHS broad authority to determine which medicines are 'essential' and at 'high risk,' potentially enabling future administrations to expand the list beyond current scope without additional legislative action.
- Information sharing among federal agencies about manufacturing locations and production volumes, while protected from FOIA disclosure, may create a centralized database of sensitive pharmaceutical infrastructure that could become a target for foreign intelligence or cyberattack if security measures fail.
- The bill's reliance on 'public-private partnerships' for supply chain mapping may incentivize pharmaceutical companies to share proprietary data with government in exchange for regulatory benefits or priority access to Defense Production Act authorities, creating an asymmetric information advantage.
- Annual reporting requirements to Congress on supply chain vulnerabilities may inadvertently publicize weaknesses in U.S. pharmaceutical manufacturing, potentially signaling to adversaries which drugs or ingredients are most vulnerable to disruption.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
The bill strengthens public health and national security by creating transparency into pharmaceutical supply chains and identifying vulnerabilities that could lead to drug shortages affecting patients with chronic conditions. Citizens gain visibility into supply chain risks and federal coordination to mitigate them, with no direct restrictions on citizen rights or remedies.
Who stands to gain
- domestic pharmaceutical manufacturers
- contract manufacturing organizations (CMOs)
- advanced manufacturing technology providers
- pharmaceutical supply chain software and analytics vendors
Named in the bill
Department of Health and Human Services (HHS), Executive Order 13944, Defense Production Act of 1950, National Response Framework, Federal Food, Drug, and Cosmetic Act, Homeland Security Act of 2002, 21st Century Cures Act, House Committee on Energy and Commerce
Where it stands
2 cosponsors: 2 Republicans.
- Jun 26, 2025 — Introduced · Congress.gov: “Introduced in House”
- Jun 26, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
6 lobbying clients named this bill on 10 disclosure filings across 3 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,840,000 in lobbying spend. A filing names 8 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 82% of bills with at least one filing.
Doris Matsui, the sponsor, reported $1,026,688 in PAC receipts in the 2026 cycle.
- Association for Clinical Oncology — $600,000 on 2 filings
- Phlow Corporation — $370,000 on 1 filing
- The United States Pharmacopeial Convention — $350,000 on 3 filings
- Vizient Inc — $320,000 on 1 filing
- Phlow Corporation — $180,000 on 2 filings
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (9,300 characters) on Aug 12, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“Congress moves to map hidden vulnerabilities in America's drug supply” QuorumCivic. https://share.quorumcivic.app/bill/119/hr4191 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.